Researchers Disagree On NIH Plan To Improve Its Peer-Review Process

Sidebar: The RGA's Committee's Recommendation CREATIVE BOOST: An alternative proposal from UCSF’s Keith Yamamoto adds innovation into the peer-review equation. As officials at the National Institutes of Health consider a proposal to change the peer-review process by which grant applications are considered, researchers offer divided opinions on whether the plan would help or hinder science. A highly disputed issue -- whether the changes would foster creative, innovative science -- has le

Written byThomas Durso
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

Sidebar: The RGA's Committee's Recommendation

While calling the current system good, NIH is seeking a better way to judge the more than 30,000 applications it receives annually. The process now in place has come under fire by scientists who are upset over the way the agency distributes NIH's limited research funds. Many feel it discourages the pursuit of cutting-edge research in favor of research with "guaranteed" results.

"The applicant community -- the scientists, the working investigators -- recognize that creativity is something that is not given the benefit of review. In fact, there's a penalty for putting creative ideas into applications," contends Keith R. Yamamoto, professor and chairman of the department of cellular and molecular pharmacology at the University of California, San Francisco, who developed the much-discussed alternative to the NIH proposal. "That seems to encourage run-of-the-mill, conventional science."

The proposal now on the table (see inclusion at right) is ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies